Novartis Receives Approval for Itvisma Gene Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 39 minutes ago
0mins
Source: NASDAQ.COM
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 156.720
Low
112.00
Averages
127.75
High
143.00
Current: 156.720
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novartis Receives Approval for Itvisma Gene Therapy
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
See More
Novartis Secures EU Approval for Itvisma to Treat Spinal Muscular Atrophy
- New Treatment Option: Novartis's Itvisma (onasemnogene abeparvovec) has received EU approval, becoming the first gene replacement therapy for the broad population of 5q spinal muscular atrophy, marking a significant breakthrough in treatment options.
- Clinical Research Support: The approval is based on data from the registrational STEER study and supportive Phase IIIb STRENGTH and Phase I/II STRONG studies, demonstrating Itvisma's efficacy and safety in improving patient health outcomes.
- Market Potential: With the launch of Itvisma, Novartis is poised to capture a leading position in the European market, addressing the urgent need for spinal muscular atrophy treatments, thereby driving future revenue growth for the company.
- Market Reaction: Although Novartis shares closed at 125.00 Swiss francs, down 1.25%, the approval of the new therapy is expected to have a positive long-term impact on the company's stock price.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
Antares Therapeutics Partners with Novartis in $1.9B Cancer Drug Deal
- Collaboration Overview: Antares Therapeutics has entered into a collaboration with Novartis valued at up to $1.9 billion, which includes an upfront payment of $105 million and milestone payments potentially reaching $1.8 billion, indicating Novartis's confidence in Antares's development of small-molecule oncology drugs.
- Market Potential: The partnership aims to develop small-molecule therapies targeting oncology areas that have been challenging to address therapeutically, which is expected to accelerate the market introduction of new treatments, thereby enhancing both companies' competitiveness in cancer care.
- Strategic Significance: Antares CEO Adam Friedman noted that this collaboration will leverage Novartis's world-class development capabilities and global reach, enabling Antares to translate scientific advancements into transformative therapies more rapidly, reflecting the increased deal-making activity among Big Pharma amid looming patent expirations.
- Industry Context: This partnership comes at a time when major pharmaceutical companies are actively pursuing deals due to the impending expiration of patents on some blockbuster drugs, highlighting a robust demand for new drug development and ongoing investment in the market.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 160.39 points to 29,507.66, reflecting investor optimism that could drive positive performance in upcoming trading sessions.
- Active Stocks: Wendy's Company (WEN) increased by $1.4644 in pre-market trading with a volume of 18,113,633 shares, currently priced at $7.72, which is 96.49% of its target price of $8, indicating strong buying interest.
- Short Interest Rates: Absci Corporation (ABSI) and Sunrun Inc. (RUN) have short interest days of 7.48 and 7.90 respectively, suggesting high demand for these stocks that may influence their future price movements.
- Target Price Analysis: Novartis AG (NVS) is currently priced at $153.51, exceeding its target price of $142 by 108.11%, demonstrating market confidence in its future growth and potentially attracting more investor attention.
See More
Novartis Receives Approval for Itvisma Gene Therapy
- Gene Therapy Approval: Novartis's Itvisma gene therapy has received approval from the European Commission, specifically designed for treating patients with 5q spinal muscular atrophy, marking a significant advancement in the rare disease sector and expected to enhance the company's competitive position in this market.
- Successful Clinical Trials: Itvisma demonstrated impressive results in the STEER clinical program, with both the Phase 1/2 STRONG trial and Phase 3b STRENGTH trial showing significant efficacy, as treated subjects exhibited an average improvement of 2.39 points on the Hammerstein Functional Motor Scale, indicating the therapy's effectiveness and sustainability.
- Market Exclusivity: Itvisma is now the only approved gene therapy for adults with SMA in the European Union, further solidifying Novartis's leadership in the gene therapy space while providing a new revenue stream for the company.
- Competitive Product Scrutiny: Novartis's other drug, Zolgensma, is under review due to liver-related side effects in infants, which clarifies Itvisma's market outlook and may attract more patients to choose this therapy.
See More
Novartis Secures EU Approval for Itvisma to Treat Spinal Muscular Atrophy
- New Treatment Option: Novartis's Itvisma (onasemnogene abeparvovec) has received EU approval, becoming the first gene replacement therapy for the broad population of 5q spinal muscular atrophy, marking a significant breakthrough in treatment options.
- Clinical Research Support: The approval is based on data from the registrational STEER study and supportive Phase IIIb STRENGTH and Phase I/II STRONG studies, demonstrating Itvisma's efficacy and safety in improving patient health outcomes.
- Market Potential: With the launch of Itvisma, Novartis is poised to capture a leading position in the European market, addressing the urgent need for spinal muscular atrophy treatments, thereby driving future revenue growth for the company.
- Market Reaction: Although Novartis shares closed at 125.00 Swiss francs, down 1.25%, the approval of the new therapy is expected to have a positive long-term impact on the company's stock price.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
Antares Therapeutics Partners with Novartis in $1.9B Cancer Drug Deal
- Collaboration Overview: Antares Therapeutics has entered into a collaboration with Novartis valued at up to $1.9 billion, which includes an upfront payment of $105 million and milestone payments potentially reaching $1.8 billion, indicating Novartis's confidence in Antares's development of small-molecule oncology drugs.
- Market Potential: The partnership aims to develop small-molecule therapies targeting oncology areas that have been challenging to address therapeutically, which is expected to accelerate the market introduction of new treatments, thereby enhancing both companies' competitiveness in cancer care.
- Strategic Significance: Antares CEO Adam Friedman noted that this collaboration will leverage Novartis's world-class development capabilities and global reach, enabling Antares to translate scientific advancements into transformative therapies more rapidly, reflecting the increased deal-making activity among Big Pharma amid looming patent expirations.
- Industry Context: This partnership comes at a time when major pharmaceutical companies are actively pursuing deals due to the impending expiration of patents on some blockbuster drugs, highlighting a robust demand for new drug development and ongoing investment in the market.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator rose by 160.39 points to 29,507.66, reflecting investor optimism that could drive positive performance in upcoming trading sessions.
- Active Stocks: Wendy's Company (WEN) increased by $1.4644 in pre-market trading with a volume of 18,113,633 shares, currently priced at $7.72, which is 96.49% of its target price of $8, indicating strong buying interest.
- Short Interest Rates: Absci Corporation (ABSI) and Sunrun Inc. (RUN) have short interest days of 7.48 and 7.90 respectively, suggesting high demand for these stocks that may influence their future price movements.
- Target Price Analysis: Novartis AG (NVS) is currently priced at $153.51, exceeding its target price of $142 by 108.11%, demonstrating market confidence in its future growth and potentially attracting more investor attention.
See More
